Management of Paecilomyces lilacinus paecilomycosis: Contribution of susceptibility testing, cure by surgery and voriconazole;Prise en charge d'un cas de paecilomycose à Paecilomyces lilacinus: Apport de l'antifongigramme, guérison par chirurgie et voriconazole

Journal de Mycologie Medicale

Volumn 14, Issue 3, 2004, Pages 134-136

  Chandenier, J ^a   Ledu, S ^a   Machet, M C ^a   Prudhomme, A ^a   Bastides, F ^a   Bacq, Y ^a   Chandenier, B ^a   Barrabes, A ^a   Machet, L ^a   Richard Lenoble, D ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Corticotherapy; Dermatology; E test; Paecilomyces; Surgery; Voriconazole

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; ITRACONAZOLE; PREDNISONE; VORICONAZOLE;

AGED; ARTICLE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DERMATITIS; DRUG DOSE REDUCTION; DRUG SENSITIVITY; E TEST; FUNGUS CULTURE; FUNGUS HYPHAE; FUNGUS SPORE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MYCOSIS; PAECILOMYCES LILACINUS; PAECILOMYCOSIS; SKIN BIOPSY; TEMPORAL ARTERITIS;

FUNGI; PAECILOMYCES; PAECILOMYCES LILACINUS;

EID: 6344254996     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bessis D, Guilhou JJ. La pathologie dermatologique en Médecine interne. Arnette 1999;487-91.
2. Castro LGM, Salebian A, Stto MN. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecylomyces species infections. J Med Vet Mycol 1990;28:15-26.
3. De Hoog GS. Risk assessment of fungi reported from humans and animals. Mycoses 1996;39:407-17.
4. Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001;39:1360-7.
5. Fleming RV, Walsh TJ, Anaissie EJ. Emerging and less common fungal pathogens. Infect Dis Clin North Am 2002;16:915-33.
6. Hilmarsdottir I, Thorsteinsson SB, Asmundsson P, Bodvarsson M, Arnadottir M. Cutaneous infection caused by Paecilomyces lilacinus in a renal transplant patient: treatment with voriconazole. Scand J Infect Dis 2000;32:331-2.
7. Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997;53:539-49.
8. Lovell RD, Moll M, Allen J, Cicci LG. Disseminated Peacilomyces lilacinus infection in a patient with AIDS. AIDS Read 2002;12:212-3.
9. Marchese SM, Smoller BR. Cutaneous Paecilomyces lilacinus infection in a hospitalized patient taking corticosteroids. Int J Dermatol 1998;37:438-41.
10. Roque J, Navarro M, Toro G, Gonzalez I, Pimstein M, Venegas E. Paecilomyces lilacinus systemic infection in an immunocompromised child. Rev Med Chil 2003;131:77-80.
11. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002;34:1415-7.